Item 1A. Risk Factors

There have been no material changes in our risk factors disclosed in Part 1, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuer Purchases of Equity Securities


	Total Number of Shares Purchased (1)	Average Price Paid per Share		Total Number of Shares Purchased as Part of the Publicly Announced Common Stock Repurchase Plan (2)	Maximum Approximate Dollar Value of Shares that may yet be Purchased under the Common Stock Repurchase Plan (2)
Period
October 1 to 31, 2022	363,955	$	233.07	361,638	$	696,098,299

November 1 to 8, 2022	100,511	$	240.60	99,769	$	672,096,857
November 9 to 30, 2022	195,721	$	253.82	192,981	$	4,951,046,542

December 1 to 31, 2022	257,196	$	247.31	254,359	$	4,888,117,684
Total	917,383			908,747

(1) During the three months ended December 31, 2022, pursuant to the terms of our restricted stock program, the Company purchased 8,636 shares at the then-market value of the shares to satisfy certain tax withholding requirements for employees upon the vesting of their restricted shares.

(2) On November 9, 2022, the Board of Directors authorized the repurchase of $5 billion of our common stock, replacing in its entirety the previous 2019 authorization to purchase up to $5 billion of common stock included in the table above as follows:


Date of Approval
November 2019			$5 billion
November 2022			$5 billion

There is no expiration date for the new common stock repurchase authorization.

Previous: Item 4. Controls and Procedures · Next: Item 5. Other Information